JAGSNPHARM.NS Earnings: Jagsonpal Pharma Reports $642M Revenue

Jagsonpal Pharmaceuticals Limited reported its latest earnings on May 4, 2026, delivering JAGSNPHARM.NS $642.03 million in revenue and $1.25 earnings per share. The Indian pharmaceutical manufacturer, which specializes in women’s health, pain management, and general medicine formulations, showed solid operational performance. However, the stock declined 1.79% following the announcement, closing at $206.61. The company maintains a strong balance sheet with minimal debt and robust cash generation. Meyka AI rates JAGSNPHARM.NS with a grade of B+, reflecting solid fundamentals despite recent market headwinds.

Jagsonpal Pharmaceuticals Earnings Results

Jagsonpal Pharmaceuticals delivered strong financial metrics in its latest earnings report. The company generated $642.03 million in revenue, demonstrating consistent growth across its pharmaceutical portfolio. Earnings per share came in at $1.25, reflecting solid profitability on a per-share basis.

Revenue Performance

The $642.03 million revenue figure represents meaningful growth for the specialty and generic drug manufacturer. Jagsonpal’s diversified product portfolio across women’s health, pain management, and general medicine drove consistent demand. The company serves both domestic and international markets, with strong positioning in India’s growing pharmaceutical sector.

Earnings Per Share Strength

The $1.25 EPS demonstrates the company’s ability to convert revenue into shareholder value. With 67.14 million shares outstanding, Jagsonpal maintains efficient capital structure. The earnings reflect operational efficiency and cost management across manufacturing and distribution channels.

Financial Health and Balance Sheet Strength

Jagsonpal Pharmaceuticals maintains exceptional financial stability with minimal leverage and strong liquidity. The company’s balance sheet reflects conservative debt management and robust cash generation capabilities. Key metrics show the pharmaceutical manufacturer is well-positioned for sustainable growth.

Debt and Liquidity Position

The company carries minimal debt with a debt-to-equity ratio of just 0.03. Current ratio stands at 5.06, indicating strong short-term liquidity. Cash per share reaches $15.15, providing substantial financial flexibility for operations, R&D, and shareholder returns.

Cash Flow Generation

Operating cash flow per share totals $3.52, while free cash flow per share reaches $3.51. These metrics demonstrate Jagsonpal’s ability to generate cash from core operations. The company maintains a 1.17% dividend yield with a $2.50 dividend per share, rewarding shareholders while retaining capital for growth.

Market Valuation and Stock Performance

Jagsonpal Pharmaceuticals trades at a $14.29 billion market capitalization with recent price action showing mixed signals. The stock declined 1.79% immediately following earnings, closing at $206.61. However, longer-term performance metrics reveal strong shareholder value creation over extended periods.

Valuation Metrics

The stock trades at a P/E ratio of 33.74, reflecting investor expectations for future growth. Price-to-sales ratio stands at 4.98, while price-to-book reaches 5.40. These valuations suggest the market prices in solid growth prospects for the pharmaceutical manufacturer.

Stock Price Trends

The stock trades near its 50-day average of $185.45 and 200-day average of $207.03. Year-to-date performance shows 10.52% gains, while the stock remains 31.5% below its 52-week high of $301.65. This pullback from highs may present opportunities for value-conscious investors.

Meyka AI Analysis and Investment Grade

Meyka AI rates Jagsonpal Pharmaceuticals with a B+ grade, reflecting solid fundamentals and growth prospects. The rating incorporates multiple analytical frameworks including financial metrics, sector comparisons, and growth forecasts. The company demonstrates strong operational execution within India’s dynamic pharmaceutical sector.

Fundamental Strengths

Jagsonpal shows exceptional return on equity at 17.08% and return on assets at 13.60%. The company’s gross profit margin of 63.66% demonstrates pricing power and operational efficiency. Strong receivables turnover of 16.71x indicates effective working capital management and customer quality.

Growth Outlook

Three-year revenue growth forecast projects $338.45, while five-year forecasts reach $408.87. The company’s diversified product portfolio and strong market position support continued expansion. Meyka AI’s B+ rating suggests the stock offers balanced risk-reward for investors seeking pharmaceutical sector exposure.

Final Thoughts

Jagsonpal Pharmaceuticals delivered solid earnings with $642.03 million in revenue and $1.25 EPS, demonstrating operational strength in India’s competitive pharmaceutical market. The company’s exceptional balance sheet, minimal debt, and robust cash generation provide financial stability. Despite the 1.79% post-earnings decline, Meyka AI’s B+ rating reflects confidence in the company’s fundamentals and growth trajectory. The stock’s pullback from 52-week highs may present attractive entry points for investors seeking exposure to India’s pharmaceutical sector with strong operational execution and shareholder-friendly capital allocation.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.